308080 — ViGenCell Balance Sheet
0.000.00%
- KR₩62bn
- KR₩25bn
- KR₩279m
Annual balance sheet for ViGenCell, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 16,185 | 65,448 | 69,074 | 53,412 | 45,183 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,145 | 103 | 743 | 850 | 627 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 17,660 | 66,724 | 69,892 | 54,442 | 45,877 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,824 | 16,120 | 26,968 | 23,498 | 18,818 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 23,051 | 116,979 | 99,373 | 81,049 | 67,346 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 56,314 | 10,189 | 8,353 | 8,474 | 8,002 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 57,122 | 12,091 | 9,731 | 9,560 | 9,321 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | -34,072 | 104,887 | 89,643 | 71,489 | 58,026 |
Total Liabilities & Shareholders' Equity | 23,051 | 116,979 | 99,373 | 81,049 | 67,346 |
Total Common Shares Outstanding |